Clinical Trials & Research

Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed its USD$105 million Series D financing. This round of funding was co-led by existing investor Rotating Boulder Fund, new investor Walvax Biotechnology Co., Ltd. and Sunshine Riverhead Capital, with support from existing investors Sangel Capital and new investors:
0 Comments
VelosBio announced that the first patient has been dosed in a Phase 2 trial of VLS-101 in patients with solid tumors. VLS-101, the company’s lead product candidate, is an antibody-drug conjugate (ADC) that targets ROR1. ROR1 is a cell-surface protein that is expressed during embryofetal development but disappears before birth and is usually not expressed
0 Comments
JSR Life Sciences is set to expand European gene-to-GMP biologics manufacturing facilities of its affiliate companies KBI Biopharma and Selexis in Geneva, Switzerland. With a combined area of 8,700m² in the Stellar 32 campus within Geneva’s ZIPLO, the newly expanded facility will co-locate primary European operations of both companies. KBI Biopharma’s expanded facility will provide
0 Comments
Astellas Pharma has secured fast track status from the US Food and Drug Administration (FDA) to develop ASP0367/MA-0211 (ASP0367) as a potential treatment for primary mitochondrial myopathies (PMM). PMM is a complex mitochondrial disease in which genetic mutations mainly impair the function of mitochondria that may result in reduced muscle function, reduced endurance to exercise,
0 Comments
Xeris Pharmaceuticals, a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced it was granted fast track designation by the Food and Drug Administration (FDA) for the investigation of XP-0863 (diazepam non-aqueous injection) for the treatment of acute repetitive seizures. Xeris’ XP-0863 was previously granted
0 Comments
AstraZeneca’s TAGRISSO (osimertinib) has received acceptance for its supplemental New Drug Application (sNDA) and has also been granted Priority Review in the US for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent. While up to
0 Comments
ImmunityBio and NantKwest have dosed the first patient in phase I clinical study of a novel Covid-19 vaccine candidate called hAd5-Covid-19. NantKwest and ImmunityBio’s hAd5-Covid-19 is a novel Covid-19 vaccine candidate designed to target the inner nucleocapsid (N) and the outer spike (S) protein, as well as activate both T cells and antibodies against the
0 Comments
EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, announced it has recently entered into an exclusive license agreement with Diurnal Group plc, a specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, for the registration and commercialization of Alkindi for pediatric adrenocortical insufficiency (AI) in Switzerland.
0 Comments
Novartis has secured orphan drug designation from the US Food and Drug Administration (FDA) for its branaplam (LMI070) to treat Huntington’s disease (HD). Branaplam has been demonstrated to decrease levels of mutant huntingtin protein in preclinical models, said Novartis. Based on the results, Novartis aims to begin a development programme for branaplam to determine if
0 Comments
Gilead Sciences announced 48-week data from the BRAAVE 2020 study, a Phase 3 clinical trial evaluating the safety and efficacy of switching to Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in virologically suppressed adults living with HIV who self-identified as Black or African American. These data presented at IDWeek 2020 show that
0 Comments
1. Burke D, Fullen BM, Stokes D, Lennon O. Neuropathic pain prevalence following spinal cord injury: a systematic review and meta-analysis. Eur J Pain. 2017;21:29–44. CAS  Article  Google Scholar  2. Hadjipavlou G, Cortese AM, Ramaswamy B. Spinal cord injury and chronic pain. BJA Educ. 2016;16:264–8. Article  Google Scholar  3. Gerke MB, Duggan AW, Xu L,
0 Comments
1. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150–63. Article  Google Scholar  2. Zeiser R, Blazar BR. Acute graft-versus-host disease. N Engl J Med. 2018;378:586.
0 Comments
Oct 21 2020 Sony has today introduced the LMD-X3200MD 32-inch medical grade LCD monitor, enhancing surgical workflow with 4K HDR color imaging and innovative technology. With a sleek, ergonomic design optimized for environments including hospital operating rooms, surgical centers, and clinics, the medical monitor delivers an image quality closer to reality than ever before. Designed
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 21 2020 Helping to explain what makes SARS-CoV-2 so capable of infecting human cells, researchers in two independent studies discovered that the virus’s spike protein recognizes and binds a protein on the human cell surface called neuropilin-1. This facilitates its ability to enter and infect cells, they suggest. Demonstrating a
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 21 2020 A team of researchers at Osaka University, in collaboration with the University of Bordeaux and the Bergonié Institute in France, has succeeded in terahertz imaging of early-stage breast cancer less than 0.5 mm without staining, which is difficult to identify even by pathological diagnosis. Their work provides a
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 21 2020 The coronavirus SARS-CoV-2 is known to infect cells via the receptor ACE2. An international research team under German-Finnish coordination has now identified neuropilin-1 as a factor that can facilitate SARS-CoV-2 entry into the cells’ interior. Neuropilin-1 is localized in the respiratory and olfactory epithelia, which could be a
0 Comments